Rheumatology

Study: Medicare's Lost Savings Due to Delayed Adalimumab Biosimilar Entry

July 12th 2021

By Tony Hagen

Medicare lost out on over $2 billion in savings as adalimumab biosimilars were sidelined by patent restrictions, said investigators who recommended patent reforms.

Amgen US Biosimilar Trends Report Highlights Price Discounts

July 10th 2021

By Tony Hagen

Biosimilars are launching at significant discounts to reference products and capturing increasing market share, according to an Amgen report.

Panel Discusses Generic, Biosimilar Marketplace Sustainability

July 9th 2021

By Tony Hagen

Following the release of a whitepaper on sustainable generics and biosimilars markets, members of a trade association discussed concerning trends for the industry.

IGBA Takes Aim at Pricing Pressure and Post–COVID-19 Protectionism

July 8th 2021

By Tony Hagen

In a white paper, the International Generic and Biosimilar Medicines Association (IGBA) describes industry dynamics that it says affect market sustainability and patient access.

Bioeq Signs Another Marketing Deal for Ranibizumab Candidate

July 7th 2021

By Tony Hagen

Ahead of receiving regulatory approval for a "wet" age-related macular degeneration biosimilar candidate, a broad-based commercialization deal is inked.

Alvotech's Ustekinumab Candidate Reaches Clinical Trial Milestone

July 6th 2021

By Tony Hagen

AVT04 (ustekinumab) if approved would be targeted at an estimated $7.7 billion market for the reference product, Stelara.

Leading Biosimilars Headlines From June 2021

July 5th 2021

The Center for Biosimilars® provided news and insight during June 2021 in the form of interviews with key opinion leaders and coverage of major events. Catch up on what you missed.

Patient Advocacy Groups Offer Support for BIOSIM Act

July 1st 2021

By Tony Hagen

The BIOSIM Act would increase the add-on payment for use of a biosimilar, thereby incentivizing practitioners to use these products more often, according to proponents of the bill.

Authors Propose Elimination of "Double Standard" for Biosimilars

June 28th 2021

By Deana Ferreri, PhD

Authors of an opinion piece suggest that a "reliance" approach to biosimilar approval could lead to global standards for acceptance that cut down on wasted review time and obsolete clinical investigation.

Amgen Executive Weighs the Challenges for Interchangeable Biosimilars

June 25th 2021

By Tony Hagen

A turning point for interchangeable biosimilars has arrived, as the first may be approved this year, but many questions about these agents have yet to be answered, according to Laura Sim, senior counsel for Amgen.